Blog

BRIEF-Janssen To Acquire Benevir Biopharm To Advance Immunotherapy Regimens – Reuters

BRIEF-Janssen To Acquire Benevir Biopharm To Advance Immunotherapy Regimens
Reuters
May 2 (Reuters) – Johnson & Johnson: * JANSSEN TO ACQUIRE BENEVIR BIOPHARM TO ADVANCE IMMUNOTHERAPY REGIMENS. * JANSSEN BIOTECH- ENTERED INTO A DEFINITIVE AGREEMENT UNDER WHICH IT WILL ACQUIRE BENEVIR BIOPHARM. * JANSSEN BIOTECH – BENEVIR WILL MAINTAIN

2018-05-02 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.